Your session is about to expire
← Back to Search
A Study of LY3871801 in Healthy Asian and Non-Asian Participants
Phase 1
Waitlist Available
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose on day 1 up to postdose on day 17
Summary
This trial tests a new drug, LY3871801, to see if it is safe and well-tolerated when taken multiple times. It includes healthy participants from both Asian and Non-Asian backgrounds. Researchers will measure how much of the drug enters the bloodstream and how long it remains in the body.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ predose on day 1 up to postdose on day 17
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose on day 1 up to postdose on day 17
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary study objectives
PK: Area Under the Concentration Versus Time Curve (AUC) of LY3871801
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3871801
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3871801 (Part B)Experimental Treatment1 Intervention
LY3871801 administered orally in Chinese Participants.
Group II: LY3871801 (Part A)Experimental Treatment1 Intervention
LY3871801 administered orally in Japanese and Non-Asian Participants.
Group III: Placebo (Part B)Placebo Group1 Intervention
Placebo administered orally in Chinese Participants.
Group IV: Placebo (Part A)Placebo Group1 Intervention
Placebo administered orally in Japanese and Non-Asian Participants.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3871801
2022
Completed Phase 1
~90
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Eli Lilly and CompanyLead Sponsor
2,680 Previous Clinical Trials
3,466,352 Total Patients Enrolled
Study DirectorEli Lilly and Company
1,391 Previous Clinical Trials
428,809 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You smoke more than 10 cigarettes every day.You have a history of or current serious heart, lung, liver, kidney, stomach, hormone, blood, or brain disorders that may affect how drugs work in your body.